IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
// Romaine I. Fernando 1 , Duane H. Hamilton 1 , Charli Dominguez 1 , Justin M. David 1 , Kristen K. McCampbell 1 , Claudia Palena 1 1 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA Correspondence to: Claudia Palena, email: palenac@mail.nih.gov Keywords: erlotinib, tumor resistance, IL-8, epithelial-mesenchymal transition Received: October 02, 2015 Accepted: May 14, 2016 Published: May 27, 2016 ABSTRACT A signaling pathway that is frequently deregulated in human carcinomas and has been explored as a therapeutic target involves the activation of the epidermal growth factor receptor (EGFR). Inhibition of EGFR via the small molecule inhibitors erlotinib and gefitinib commonly results in tumor resistance, even in patients with EGFR-mutant tumors that initially show substantial clinical responses. This study was designed to broaden our understanding of the molecular mechanisms of acquired resistance to erlotinib in lung cancer cells bearing wild type or mutated EGFR. We report here that generation of erlotinib-resistant lung cancer cells in vitro resulted in a phenotypic alteration reminiscent of an epithelial-mesenchymal transition (EMT) concomitant with a robust upregulation of the IL-8/IL-8R axis. Our results also demonstrate that upregulation of p38 MAPK signaling is responsible for the enhanced IL-8 secretion in the erlotinib-resistant tumor cells. Blockade of IL-8 signaling effectively reduced mesenchymal features of the resistant cells and also markedly enhanced their susceptibility to erlotinib. These results provide a rationale for the development of new therapeutic approaches involving blockade of IL-8 signaling for the management of acquired resistance to EGFR inhibition in patients with lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“The acquisition of EMT features by tumors resistant to EGFR inhibition has been previously described both in preclinical studies and with clinical samples [35].”
BackgroundThe Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598 · cited 1×
“Other mechanisms have been described in the remaining patients, including enhanced expression of c-MET [12, 13], activation of the nuclear factor-κB (NF-κB) pathway [14], or activation of the AXL kinase [15].”
BackgroundActivation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156 · cited 1×
“Unlike colon carcinoma, where tumors harboring mutant KRAS are known to be resistant to EGFR inhibition [33], the significance of KRAS mutations upon the benefit of antiEGFR therapies in patients with lung cancer remains unclear [34].”
BackgroundPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · cited 1×
“Other mechanisms have been described in the remaining patients, including enhanced expression of c-MET [12, 13], activation of the nuclear factor-κB (NF-κB) pathway [14], or activation of the AXL kinase [15].”
BackgroundByers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Multiple control of interleukin-8 gene expression
Hoffmann, E., Dittrich-Breiholz, O., Holtmann, H., & Kracht, M. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.5.847 · Cited by 1,058 · cited 2×
“We have shown that erlotinib-resistant cells have a marked upregulation of the cytokine/stress-inducible p38 MAPK and its phosphorylated form, which is known to regulate IL-8 secretion by mediating the stabilization of IL-8 mRNA [45, 46], and that blockade of p38 via a small molecule inhibitor is able to reduce the se…”
BackgroundAcquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · cited 1×
“Understanding the mechanisms involved in acquired resistance to EGFR inhibition has been a subject of intense investigation [10].”
Background
Cited by
EMT and inflammation: inseparable actors of cancer progression
Suarez‐Carmona, M., Lesage, J., Cataldo, D., & Gilles, C. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12095 · Cited by 566
Fousek, K., Horn, L. A., & Palena, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107692 · Cited by 359
Self-citationTumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
“Another study showed that neutralizing IL-8 can alleviate resistance to erlotinib in NSCLC, thereby enhancing sensitivity in chemotherapy-resistant cells.(262) Inhibition of CXCR2 with SB225002 also alleviated the IL-8-related resistance in sorafenibresistant ovarian tumor cells.”
BackgroundNing, Y., Cui, Y., Li, X., Cao, X., Chen, A., Xu, C., Cao, J., & Luo, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.022 · Cited by 75
Lee, S. W. L., Seager, R. J., Litvak, F., Spill, F., Sieow, J. L., Leong, P. H., Kumar, D., Tan, A. S. M., Wong, S. C., Adriani, G., et al. (2020) · Integrative Biology · doi:10.1093/intbio/zyaa007 · Cited by 60
Metadata
- Authors
- Fernando, R. I., Hamilton, D. H., Dominguez, C., David, J. M., McCampbell, K. K., & Palena, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-05-27
- Volume
- 7
- Issue
- 27
- Pages
- 42031-42044
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2405571890
- Cited by
- 61
- References
- 13
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. https://app.cochat.ai/papers/10.18632/oncotarget.9662
- The paper
- Fernando, R. I., Hamilton, D. H., Dominguez, C., David, J. M., McCampbell, K. K., & Palena, C. (2106). IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget. https://doi.org/10.18632/oncotarget.9662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.